OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, a leader in the specialty pharmacy industry, is excited to announce the availability of Galderma's latest medication, NEMLUVIO® (nemolizumab-ilto), for the treatment of Prurigo Nodularis in adults. This partnership marks a significant advancement in the therapeutic options available to patients suffering from this chronic, debilitating skin condition..

内布拉斯加州奥马哈——（商业新闻短讯）——Amber Specialty Pharmacy是专业制药行业的领导者，很高兴宣布Galderma的最新药物NEMLUVIO®（nemolizumab ilto）可用于治疗成人结节性痒疹。这种合作关系标志着患有这种慢性衰弱性皮肤病的患者在治疗选择方面取得了重大进展。。

Prurigo Nodularis, characterized by intensely itchy nodules of the skin, significantly impacts patients' quality of life. The introduction of Galderma's innovative therapy offers new hope for effective management and symptom relief.

结节性痒疹的特征是皮肤结节强烈发痒，严重影响患者的生活质量。。

'We are thrilled to offer our patients access to Galderma's cutting-edge medication for Prurigo Nodularis,' said Kristin Williams, president of Amber Specialty Pharmacy. 'This collaboration aligns with our commitment to providing the best possible care and improving the lives of those affected by rare and chronic conditions.'.

Amber Specialty Pharmacy总裁克里斯汀·威廉姆斯（KristinWilliams）说：“我们很高兴为患者提供高德玛（Galderma）治疗结节性痒疹的尖端药物。”这种合作符合我们提供最佳护理和改善受罕见和慢性病影响者生活的承诺。”。

Amber Specialty Pharmacy will begin offering Galderma's new medication immediately, ensuring patients have timely access to this breakthrough therapy. For more information, please visit www.AmberPharmacy.com or contact Amber Specialty Pharmacy’s customer service team at (888) 370-1724.

琥珀专业药房将立即开始提供高德玛的新药，确保患者能够及时获得这一突破性治疗。有关更多信息，请访问www.AmberPharmacy.com或致电（888）370-1724联系琥珀专业药房的客户服务团队。

# # #

# # #

About Amber Specialty Pharmacy

关于琥珀专业药房

Amber Specialty Pharmacy is a pioneer in providing specialty pharmacy services and patient support. With a focus on rare and chronic conditions, Amber Specialty Pharmacy delivers comprehensive care and innovative solutions that enhance patient outcomes.

琥珀专业药房是提供专业药房服务和患者支持的先驱。琥珀专业药房专注于罕见和慢性疾病，提供全面的护理和创新的解决方案，提高患者的治疗效果。

About Galderma

关于Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. Galderma delivers an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

Galderma（SIX：GALD）是新兴的纯皮肤病学类别领导者，分布在大约90个国家。Galderma通过注射美学、皮肤科皮肤护理和治疗性皮肤病学，提供创新、科学的优质旗舰品牌和服务组合，涵盖快速增长的皮肤病学市场的所有领域。

Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

因为我们了解我们所处的皮肤塑造了我们的生活，所以我们正在为每一个皮肤故事推进皮肤病学。有关更多信息，请访问www.galdrma.com。

For more on FDA approval and indication information, visit https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo

有关FDA批准和适应症信息的更多信息，请访问https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo

Important Safety Information

重要安全信息

Indication: NEMLUVIO®(nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis. Contraindication: Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO. Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use.

适应症：NEMLUVIO®（nemolizumab-ilto）是一种白细胞介素31受体拮抗剂，用于治疗成人结节性痒疹。禁忌症：已知对nemolizumab-ilto或NEMLUVIO中的任何赋形剂过敏。警告/注意事项：据报道，使用NEMLUVIO会产生过敏反应。

If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. Adverse Events: Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular..

如果发生临床上显着的超敏反应，请立即进行适当的治疗，并停止使用NEMLUVIO。在用NEMLUVIO治疗期间避免使用活疫苗。不良事件：最常见的不良反应（发生率≥1%）是头痛，特应性皮炎，湿疹和湿疹。。

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

鼓励您向FDA报告处方药的负面副作用。访问www.fda.gov/medwatch或致电1-800-fda-1088。

Please see full Prescribing Information including Patient Information.

请参阅完整的处方信息，包括患者信息。